ema prac naion semaglutide very rare side effect 2025 A potentially blinding condition is a of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Ozempic NAION Side Effects Result
Description
Neuropsychiatric safety should be a key consideration in any clinical riskbenefit assessment associated with GLP1 anti-obesity medications and the analysis provided here contribute to thoughtful and objective decision-making and dialogue between patients and clinicians
Areas with significant skin folds, scars, or recent sunburn should be avoided
Searching for the physiological role of glucose-dependent insulinotropic polypeptide
Was the concentration 10 mg/mL or 5 mg/mL
10.1007/112_2016_3 [DOI] [PubMed] [Google Scholar] Monteleone F., Taverna S., Alessandro R., Fontana S
